

UNCLASSIFIED

AD NUMBER
ADB283894
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 2002. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9451

TITLE: Genetic Regulation of Lipid Biogenesis in Human Breast Cancer

PRINCIPAL INVESTIGATOR: James M. Ntambi, Ph.D.

CONTRACTING ORGANIZATION:

University of Wisconsin-Madison
Madison, Wisconsin 53706-1490

REPORT DATE: August 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

1113 023

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9451

Organization: University of Wisconsin-Madison

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2002	3. REPORT TYPE AND DATES COVERED Final (1 Jul 99 - 1 Jul 02)	
4. TITLE AND SUBTITLE Genetic Regulation of Lipid Biogenesis in Human Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9451	
6. AUTHOR(S) James M. Ntambi, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin-Madison Madison, Wisconsin 53706-1490 E-mail: ntambi@biochem.wisc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES 20021113 023				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) No Abstract Provided				
14. SUBJECT TERMS Breast cancer				15. NUMBER OF PAGES 19
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified		20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	13
Reportable Outcomes.....	14
Conclusions.....	15
References.....	16

GENETIC REGULATION OF LIPID BIOGENESIS IN HUMAN BREAST CANCER

PI: **James M. Ntambi**

(1) INTRODUCTION

Cancer is a debilitating disease and a leading cause of death worldwide characterized by increased and uncontrolled cell growth. To accommodate their increased rates of proliferation, cancer cell membranes are typically less stable and more fluid than those of benign cells (Ntambi, 1999). The increased fluidity of the membranes may be a requirement for increased cellular proliferation, growth, and metabolism. Assessing mechanisms to normalize membrane fluidity in cancer cells may offer great therapeutic potential for cancer treatment .

Stearoyl-CoA desaturase (SCD) is an oxidative enzyme crucial for the synthesis of unsaturated fatty acids. SCD inserts a *cis* double bond between the 9th and 10th carbons in the saturated fatty acids palmitoyl-CoA (16:0) and stearoyl-CoA (18:0) to produce palmitoleic (16:1) and oleic (18:1) acids, respectively. The monounsaturated products can then act as substrates for the synthesis of numerous cellular lipids including triglycerides, phospholipids, wax esters, and cholesterol esters. Because SCD activity increases the cellular ratio of unsaturated to saturated fatty acids, cells expressing higher levels of SCD are likely to have a higher unsaturated fatty acid component to their membranes, increasing membrane fluidity and permeability.

Both *in vivo* and *in vitro* regulation of SCD by intermediates, products, and mediators of lipid metabolism have been relatively well studied. For example, the sterol regulatory element binding proteins (SREBPs) activate expression of SCD in response to changes in cholesterol levels (Tabor, 1999). Polyunsaturated fatty acids (PUFAs) of the n-3 and n-6 categories and other lipids such as cholesterol have been shown to repress SCD promoter activity, mRNA, and protein levels in a variety of cell types (Jeffcoat, 1978; Waters, 1997; Tabor, 1998; Ntambi, 1999; Tabor, 1999;

Bené, 2001). However, PUFA and cholesterol regulation of SCD in human cancer cells has not been well characterized. Because cancer cells require elevated levels of lipogenesis and increased membrane fluidity, understanding SCD's expression and regulation in cancer may provide vital therapeutic answers to questions regarding cancer treatment.

This study employs MCF-7 and MDA-MB-231 (MDA) human breast cancer cell lines to examine differences in SCD regulation in cancer cells. MCF-7 cells express two wild-type alleles for the p53 tumor suppressor while MDA cells contain a loss-of-function mutation in the DNA binding domain of p53 (Xu, 2001). Human p53 is a 393 amino acid, four-domain protein that induces apoptosis, represses anti-apoptotic genes, and / or induces growth arrest in the G₁ phase of the cell cycle in response to cellular stress such as DNA damage. Mutations in p53, which occur in over 50% of human cancers, increase the likelihood of unregulated cellular proliferation and eventual tumor formation by inhibiting cellular response to distress signals (Chen, 1996; Weinberg, 1996; Levine, 1997; Hoffmann, 2002).

The proteins involved in the direct expression of SCD may help explain its regulation. The 57 base-pair polyunsaturated fatty acid response element (PUFA-RE) is a necessary promoter region for PUFA regulation of SCD (Figure 1; Waters, 1997; Bené, 2001). Four known transcription factors interact with the PUFA-RE, including SP-1, the SREBPs, NF-Y, and NF-1. In addition to mediating the cholesterol regulation of SCD, the SREBPs regulate the PUFA response of SCD and other lipogenic genes. Nuclear factor Y (NF-Y) and SP-1 are important in the PUFA mediated repression of fatty acid synthase (FAS), another lipogenic gene, via its PUFA-RE (Clarke, 2001). NF-Y is also involved in p53-induced cell cycle arrest and cellular senescence (Yun, 1999; Jung, 2001; Manni, 2001). Therefore, based on similarities between the downstream effects of p53, the regulation of SCD, and the importance of SCD and its associated transcription factors in lipid metabolism and cancer cell proliferation, it becomes possible that p53 may regulate SCD as a means of controlling cell growth.

Originally we hypothesized that polyunsaturated fatty acids (PUFA) inhibit cell proliferation associated with fatty acid synthesis by regulating the interaction of the mutant p53

protein with the specific motif on the promoters of the genes involved in fatty acid biosynthesis. We have found that the wild-type p53 protein significantly represses the transcription of the stearoyl-CoA desaturase gene (SCD) through the 57bp regulatory element we previously termed polyunsaturated fatty acid responsive element (PUFA-RE) (Waters, 1997). The PUFA-RE contains the SRE and CCAAT sequences known to mediate the transcriptional activation of lipogenic genes by the sterol regulatory element binding protein (SREBP) and NF-Y, respectively. Previous studies (Tabor, 1999) had proposed that by binding to the SRE and CCAAT, SREBP and NF-Y mediate PUFA-repression of lipogenic genes. We speculated that p53 might repress the transcription of the SCD1 gene through the same sequences. When we mutated the SRE and a sequence between the SRE and NFY, we did not abolish the p53-mediated repression of the SCD promoter. However when the NFY and NF-1 sequences (Fig. 1) were mutated, p53-mediated repression was abolished. These results suggest that a novel sequence the gccaatggca that comprises the NFY and NF-1 binding sites is responsible for p53-mediated repression of the SCD1 gene. In the presence of a dominant negative mutant of the NF-YA subunit the p53 does not decrease the promoter activity suggesting that the NF-Y transcription factor is required for the p53-mediated regulation.

(2) BODY

Materials and Methods

Cell Culture. MDA and MCF-7 human breast cancer cell lines were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum, 1% penicillin / streptomycin,

and 0.1% fungizone and incubated at 37 °C in 5% CO₂. Media was changed every 2 – 3 days, and cells were split upon reaching confluency.

Doxorubicin Treatments. Adriamycin (a.k.a. doxorubicin, Sigma-Aldrich) is a chemical inducer of p53, which inhibits cell growth and induces apoptosis in MCF-7 cells (Burrow, 2001; Chen, 2002). At nearly 100% confluency, MCF-7 cells were treated with varying concentrations of doxorubicin (DOX) dissolved in water. Approximately 24 hours after treatment, total cellular protein or cellular microsomes were isolated as described below.

Vector Construction. The Biotechnology Center of the University of Wisconsin – Madison synthesized the 57 base-pair (bp) wild-type sequence of the human PUFA-RE, 330-386 bp upstream of the transcription start site of the SCD1 gene. Several mutant PUFA-RE oligos were also created by mutating a region of bases between A↔C and T↔G (Figure 1). All oligonucleotides contained a BamHI sticky end on the 5' end and a HindIII sticky end on the 3' end. The inserts were cloned into BamHI / HindIII digested pTK-Luc vector (ATCC), which has a multicloning site upstream of a TK promoter and a *Firefly* luciferase reporter gene. All restriction and modification enzymes were from Promega in Madison, WI.

DNA Transfections. MDA and MCF-7 cells were cultured as described above in 60mm plates to approximately 50% confluency. 5 µg of the promoter luciferase constructs were transfected with 250 ng of phRL-null vector (Promega) as a control using Transit LT-1 Reagent (Mirus). In co-transfection experiments, 100ng of empty pCMV-NEO-BAM vector, vector containing a loss-of-function mutated p53 gene (248: O→S) (p53 mut), or vector containing wild-type p53 DNA (p53 w/t) was added to determine p53's effect on luciferase construct activity. After 48 hours of incubation at 37°C supplemented with 5% CO₂, cells were lysed using passive lysis buffer and *Firefly* and *Renilla* luciferase counts were read using Promega's Dual Luciferase Assay, and protein concentrations were determined using a Bio-Rad Bradford Assay (Bradford, 1976). Expression levels of the given promoters were normalized against a negative control.

Western Blotting & Analysis. Total cellular protein samples were extracted and isolated using the RIPA lysis method. Protein concentrations were determined using a Bio-Rad Bradford

Assay (Bradford, 1976), and 40 µg of protein was electrophoresed on a denaturing 10% acrylamide gel with an appropriate protein marker. The gel was transferred to a nitrocellulose membrane and blocked overnight at 4° C in BSA blocking buffer. The membranes were incubated with the appropriate primary antibody for 1 hour followed by the appropriate secondary antibody for 30 minutes. Blots were exposed using the ECL protein detection method.

Microsome Isolation & SCD Activity Assay. Twenty-four hours after treatment with DOX, MCF-7 cells were washed twice with cold (4°C) PBS and then once with cold (4°C) 10mM Tris, pH 7.4, containing 1 mM dithiothreitol and 0.25 M sucrose (TDS). The cells were resuspended in 1 mL of cold TDS and collected with a cell scraper. The cells were homogenized using a variable-speed polytron tissue disruptor (Biospec Products) and then centrifuged at 15,000 g for 20 min at 4°C. The cell pellet was discarded, and the supernatant was spun in an ultracentrifuge at 100,000 g for 1 h at 4°C. The supernatant was discarded, and the microsome pellet was resuspended in 100 µL of 0.1 M sodium phosphate buffer, pH 7.4. Protein was quantitated with a Bradford Assay (Bradford, 1976), and SCD activity was measured as previously described (Gomez, 2002).

(3) RESULTS

To investigate further the hypothesis of p53-mediated repression of SCD, MCF-7 cells were treated with doxorubicin (DOX), a known chemical inducer of DNA damage and the p53 pathway. DOX had been previously shown to safely induce p53 in MCF-7 cells (Hoffmann, 2002). Prior to treatment with DOX, MCF-7 cells do not show significant expression of p53, but p53 levels clearly increase upon DOX exposure (Figure 2). Levels of SCD protein decrease with p53 induction in MCF-7 cells while tubulin levels remain steady throughout DOX treatments, indicating that DOX does not affect whole-cell protein levels. Furthermore, treatment with DOX significantly decreases SCD activity as measured by tritiated-water release from stearyl-CoA in the presence of microsomes from DOX-treated MCF-7 cells (Figure 2B).

This data suggest a role for p53 as a transcription factor on SCD and provide substantial evidence for a p53-dependent repression of SCD in human breast cancer cells.

We previously demonstrated (reports 1 and 2) that the PUFA-RE of the SCD1 gene was important for p53 repression of the SCD1 gene. This was accomplished by cloning the 60 bp. PUFA-RE region into a pTK-luc vector and transfected into MCF-7 cells with empty pCMV-NEO-BAM vector, p53 mut, or p53 w/t DNA. The presence of p53 w/t DNA repressed SCD promoter activity to a degree similar to p53's effect on the entire -570-luciferase construct.

Given the relationship between p53 repression of SCD and the PUFA-RE, mutations of the PUFA-RE were created to isolate the site of p53 activity (Figure 1). It was thought that drastic alterations to its site of action would cause a loss of p53 function as indicated through repression of hSCD promoter activity. Functional p53 w/t DNA represses wild type PUFA-RE promoter activity despite mutations in the binding sites for the SREBP transcription factor and SP-1 (Figure 3A). A mutation in the SRE and part of NF-Y binding sites slightly reduces p53-mediated repression while a mutation corresponding to the region comprising the NF-Y and the NF-1 binding sites results in complete loss of repression (Fig. 3A). These results suggest that a novel sequence gccaatggca (Fig. 1) is responsible for p53-mediated repression of the SCD1 gene. To determine whether the NF-Y is one of the transcription factors involved in the p53-mediated repression of the SCD promoter a dominant negative mutant of the NF-YA subunit was cotransfected with the PUFA-RE and p53w/t and the luciferase activity was assayed 24h later. Figure 3B shows that in the presence of the dominant mutant of NF-YA subunit, p53 did not decrease the promoter activity. These results suggest the NF-Y transcription factor is one of the factors required for the p53-mediated repression of the SCD gene.




Figure 1 - The highlighted sequence indicates the PUFA-RE portion of the hSCD promoter. The mutated sequences used to determine the site of p53 activity on SCD are shown in lower case font. The boxes indicated known binding sites for transcription factors. The binding sites are labeled according to their corresponding protein with the exception of the sterol response element (SRE), which binds SREBPs. This study did not use all of these mutated sequences.




Figure 2 – Doxorubicin (DOX) mediated induction of p53 reduces SCD protein expression (A) and SCD activity (B) in MCF-7 cells. Tubulin was used as a loading control.





Figure 3 – A. MCF-7 cells were co-transfected with 5 μ g Firefly luciferase construct and 100 ng empty pCMV-NEO-BAM vector (-) or vector containing p35 wild type DNA (+). p35 reduces promoter activity on the wild type PUFA-RE, SP-1/SRE-mut, SRE/mut and SRE/NF-Y-mut,

construct. Repression is lost with a mutation in the region comprising of NFY and NF-1 binding sites. Expression levels for all constructs were normalized to the p53⁻ control. Protein levels as measured with a Bradford assay corrected firefly sums.

B. MCF-7 cells were co-transfected with 5 µg PUFA-RE and 100 ng of p53 wild type and NF-YA (the dominant negative subunit of NF-YA subunit) DNA. p53 does not reduce promoter activity in the presence of NF-YA. Expression levels for all constructs were normalized to the p53⁻ control.

(5) KEY RESEARCH ACCOMPLISHMENTS:

1. We have obtained further evidence of p53-mediated repression of the SCD gene expression by treating MCF-7 cells with doxorubicin (DOX), a known chemical inducer of DNA damage and the p53 pathway. Prior to treatment with DOX, MCF-7 cells do not show significant expression of p53, but p53 levels clearly increase upon DOX exposure (Figure 2). Treatment with DOX significantly decreases SCD activity as measured by tritiated-water release from stearoyl-CoA in the presence of microsomes from DOX-treated MCF-7 cells (Figure 2B). This data clearly shows that the decrease in SCD1 gene transcription observed when the SCD-1 promoter was transfected with the wt p53 expression construct correlates with decrease in SCD-1 activity and providing substantial evidence for a p53-dependent repression of SCD in human breast cancer cells.

2. The SRE and partial NF-Y sequences within the PUFA-RE were previously mutated individually (report 2) and yet p53 still repressed expression of the SCD1 promoter activity, suggesting another site within the PUFA-RE was the target for p53-mediated repression.

3. By performing finer mapping and mutating the region comprising the NF-Y and NF-1 of the PUFA-RE we discovered the sequence is responsible for the p53-mediated repression of the SCD1 gene.

4. By using the dominant negative form of NF-Y to deplete endogenous NF-Y protein, we demonstrated that the p53-mediated repression of the SCD1 promoter activity requires NF-Y transcription factor. A similar experiment using the dominant negative form of NF-1 will have to be performed to determine whether the NF-1 transcription factor is also required in the p53-mediated repression of the SCD gene. A possibility exists that a complex of proteins is required to mediate repression.

(6) REPORTABLE OUTCOMES

Henry Bené, David Lasky, and **Ntambi, J. M.** (2001) The Cloning and Characterization of the Human Stearoyl-CoA Desaturase Gene Promoter: Transcriptional Activation by Sterol Regulatory Element Binding Protein and Repression by Polyunsaturated Fatty Acids and Cholesterol. BBRC 284, 1194-8

Youngjin Choi, Yeonhwa Parka, Jayne M. Storkson, Michael Pariza and **James M. Ntambi** (2002) Inhibition of stearoyl-CoA Desaturase activity by the cis-9, trans-11 isomer and the trans-10, cis-12 isomer of conjugated linoleic acid in MDA-MB-231 and MCF-7 human breast cancer cells BBRC 294, 785-790.

Michael W. Cullen, Nicholas J. Ansay, Yudi A. Soesanto David A. Lasky, and **James M. Ntambi**.
The Role of Polyunsaturated Fatty Acids, Cholesterol, and p53 in the Regulation and Expression of
Stearoyl Co-A Desaturase in Human Breast Cancer Cell Lines Manuscript in Preparation

(7) CONCLUSIONS

This study has succeeded in isolating the effects of p53 on human SCD to the PUFA-RE and determining a specific site for p53 action. That p53 acts to regulate SCD in part through the PUFA-RE provides further support for the hypothesis that PUFA-dependent regulation of SCD may be related to p53. The importance of the NF-Y binding site to p53 action is also critical to understanding p53 regulation of SCD. As described earlier, NF-Y, or the CCAAT binding protein transcription factor, mediates numerous downstream effects in the p53 pathway. Perhaps these results suggest that SCD is simply another target for p53's effects on cellular growth and metabolism as mediated by NF-Y or NF-1. However, it is also possible that a novel protein binds to the region of the PUFA-RE made up of the NF-Y and NF-1 sites and further studies will be needed to address this possibility.

A significant finding of this study involves the decrease in SCD protein levels and activity in response to p53 induction by doxorubicin. p53's activity as a powerful regulator of cell-cycle progression and apoptosis has been very well characterized, but it had never been shown to directly affect genes involved in lipid metabolism, particularly SCD. Nevertheless, the physiological theory for this interaction is sound. Cancer cells are thought to require increased levels of lipid synthesis to support their increased growth and metabolic rates (Ntambi, 1999).

Therefore, induction of the p53 pathway should down-regulate lipogenic gene expression to decrease cellular growth rates.

In conclusion, this study successfully characterizes many previously unexamined aspects of stearoyl Co-A desaturase regulation in MDA and MCF-7 human breast cancer cell lines. It also raises several new questions regarding interactions between the p53 tumor suppressor, other lipogenic genes, and numerous intermediates and products of lipid metabolism. It is hoped that the questions addressed will provide impetus for future studies regarding interactions between tumor suppressors and lipogenic genes. These studies may develop new and creative ways to fight cancer, diabetes, and other diseases associated with cell growth and lipid metabolism.

(8) REFERENCES

- Bené, Henry, David Lasky, and James M. Ntambi. 2001. Cloning and Characterization of the Human Stearoyl-CoA Desaturase Gene Promoter: Transcriptional Activation by Sterol Regulatory Element Binding Protein and Repression by Polyunsaturated Fatty Acids and Cholesterol. *Biochemical and Biophysical Research Communications* 284: 1194 – 1198.
- Bradford, M. 1976. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein Dye Binding. *Analytical Biochemistry* 72: 248 – 254.
- Burrow, Matthew E., Christopher B. Weldon, Yan Tang, John A. McLachlan, and Barbara S. Beckman. 2001. Oestrogen-mediated Suppression of Tumour Necrosis Factor-alpha Induced Apoptosis in MCF-7 Cells: Subversion of Bcl-2 by Anti-oestrogens. *Journal of Steroid Chemistry & Molecular Biology* 78: 409 – 418.

- Chen, Shui-Tein, Tai-Long Pan, Ya-Chi Tsai, and Chun-Ming Huang. 2002. Proteomics Reveals Protein Profile Changes in Doxorubicin-treated MCF-7 Human Breast Cancer Cells. *Cancer Letters* 181: 95 – 107.
- Chen, Xinbin, Linda J. Ko, Lata Jayaraman, and Carol Prives. 1996. p53 Levels, Functional Domains, and DNA Damage Determine the Extent of the Apoptotic Response of Tumor Cells. *Genes & Development* 10: 2438 – 2451.
- Clarke, Steven D. 2001. Polyunsaturated Fatty Acid Regulation of Gene Transcription: A Molecular Mechanism to Improve the Metabolic Syndrome. *Journal of Nutrition* 131: 1129 – 1132.
- Gomez, F. E., Makoto Miyazaki, Young-Cheul Kim, Padma Marwah, Henry A. Lardy, James M. Ntambi, and Brian G. Fox. 2002. Molecular Differences Caused by Differentiation of 3T3-L1 Preadipocytes in the Presence of Either Dehydroepiandrosterone (DHEA) or 7-oxo-DHEA. *Biochemistry* 41: 5473 – 5482.
- Hoffman, William H., Siham Blade, Jack T. Zilfou, Jiandong Chen, and Maureen Murphy. 2002. Transcriptional Repression of the Anti-apoptotic *survivin* Gene by Wild Type p53. *Journal of Biological Chemistry* 277: 3247 – 3257.
- Jeffcoat, R., and A.T. James. 1978. The Control of Stearoyl-CoA Desaturase by Dietary Linoleic Acid. *FEBS Letters* 85: 114 – 118.
- Jung, Mun-Su, Jeanho Yun, Hee-Don Chae, Jeong-Min Kim, Sun-Chang Kim, Tae-Saeng Choi, and Deug Y. Shin. 2001. p53 and its Homologues, p63 and p73, Induce a Replicative Senescence through Inactivation of NF-Y Transcription Factor. *Oncogene* 20: 5818 – 5825.
- Levine, Arnold J. 1997. p53, the Cellular Gatekeeper for Growth and Division. *Cell* 88: 323 – 331.
- Manni, Isabella, Giuseppina Mazzaro, Aymone Gurtner, Roberto Mantovani, Ulrike Haugwitz, Karen Krause, Kurt Engeland, Ada Sacchi, Silvia Soddu, and Giulia Piaggio. 2001. NF-Y Mediates the Transcriptional Inhibition of the *cyclin B1*, *cyclin B2*, and *cdc25C* Promoters upon Induced G₂ Arrest. *Journal of Biological Chemistry* 276: 5570 – 5576.

- Ntambi, James M. 1999. Regulation of Stearoyl-CoA Desaturase by Polyunsaturated Fatty Acids and Cholesterol. *Journal of Lipid Research* 40: 1549 – 1558.
- Tabor, David E., Jae Bum Kim, Bruce M. Spiegelman, and Peter A. Edwards. 1998. Transcriptional Activation of the Stearoyl Co-A Desaturase 2 Gene by Sterol Regulatory Element Binding Protein / Adipocyte Determination and Differentiation Factor 1. *Journal of Biological Chemistry* 273: 22052 – 22058.
- Tabor, David E., Jae Bum Kim, Bruce M. Spiegelman, and Peter A. Edwards. 1999. Identification of Conserved *cis*-Elements and Transcription Factors Required for Sterol-Regulated Transcription of Stearoyl Co-A Desaturase 1 and 2. *Journal of Biological Chemistry* 274: 20603 – 20610.
- Waters, Katrina M., Carolyn W. Miller, and James M. Ntambi. 1997. Localization of a Polyunsaturated Fatty Acid Response Region in Stearoyl-CoA Desaturase Gene 1. *Biochimica et Biophysica Acta* 1349: 33 – 42.
- Weinberg, Robert A. 1996. How Cancer Arises. *Scientific America* September, 1996: 62 – 70.
- Yun, Jeanho, Hee-Don Chae, Hyon E. Choy, Jongkyeong Chung, Hyang-Sook Yoo, Moon-Hi Han, and Deug Y. Shin. 1999. p53 Negatively Regulates *cdc2* Transcription via the CCAAT-binding NF-Y Transcription Factor. *Journal of Biological Chemistry* 274: 29677 – 29682.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MEMO - IMI-S (70-1y)

15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	